Pub. Date : 2018
PMID : 29988737
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. | Fluvoxamine | cytochrome P450 family 2 subfamily D member 6 | Homo sapiens |
| 2 | CYP2D6 is involved in the biotransformation of fluvoxamine. | Fluvoxamine | cytochrome P450 family 2 subfamily D member 6 | Homo sapiens |
| 3 | Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance. | Fluvoxamine | cytochrome P450 family 2 subfamily D member 6 | Homo sapiens |
| 4 | Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance. | Fluvoxamine | cytochrome P450 family 2 subfamily D member 6 | Homo sapiens |
| 5 | Conclusion: This study demonstrated the lower efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorders with GA genotype in CYP2D6 1846G>A polymorphic marker. | Fluvoxamine | cytochrome P450 family 2 subfamily D member 6 | Homo sapiens |